Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study

Background Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring common EGFR mutations, such as exon 19 deletion or L858 point mutation. However, the effectiveness of EGFR‐TKIs for patients wi...

Cijeli opis

Bibliografski detalji

Glavni autori:	Masaki Kanazu, Masahide Mori, Madoka Kimura, Kazumi Nishino, Takayuki Shiroyama, Izumi Nagatomo, Shoichi Ihara, Kiyoshi Komuta, Hidekazu Suzuki, Tomonori Hirashima, Toru Kumagai, Fumio Imamura
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2021-01-01
Serija:	Thoracic Cancer
Teme:	Afatinib epidermal growth factor receptor erlotinib gefitinib uncommon mutation
Online pristup:	https://doi.org/10.1111/1759-7714.13718
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!